Advanced or Metastatic Cholangiocarcinoma

Inclusion Criteria:

1. Patients with advanced, pathologically unresectable or metastatic bile duct epithelial cell carcinoma;
2. Previously received a chemotherapy regimen (including gemcitabine) anti-tumor systemic therapy, but did not use albumin binding paclitaxel;
3. Age ≥18 years old and under 75 years old;
4. Predicted survival ≥3 months;
5. ECOG score 0-1;
6. Child-Pugh score\<8
7. There was at least one measurable tumor lesion with a long diameter ≥10 mm and a short diameter ≥15 mm on spiral CT. For general CT or physical examination, the maximum diameter must be ≥20mm;
8. The results of liver and kidney function and blood routine examination within 1 week before enrollment were consistent with the following conditions， ANC≥1.5×10\^9/L,PLT≥80×10\^9/L,HGB≥80g/L,Cr≤1.5×ULN,TBIL≤2.5×ULN,ALP≤2.5×ULN,AST≤2.5×ULN,ALT≤2.5×ULN
9. Patients participate voluntarily and sign informed consent forms

Exclusion Criteria:

1. Known to be severely allergic to carrilizumab, apatinib, and albumin paclitaxel;
2. Obstructive jaundice cannot be achieved 2.5×ULN after surgical intervention;
3. Patients with biliary obstruction that may occur or worsen within 4 to 6 weeks;
4. Patients with obvious coagulation mechanism disorder, active bleeding and bleeding tendency;
5. History of other malignancies within 5 years (fully treated basal cell carcinoma of the skin, out-of-situ cervix);
6. Interstitial pneumonia or pulmonary fibrosis;
7. Uncontrollable pleural effusion or ascites;
8. Severe uncontrolled medical disease, acute infection, recent history of myocardial infarction (within 3 months);
9. Pregnant or lactating mothers who refused to use appropriate contraceptive methods during the course of this study;
10. The researchers determined that the patients were not suitable for this study.